On Thursday, RBC Capital Markets raised its rating on shares of Medtronic plc (NYSE:MDT) from Sector Perform to Outperform. The firm also increased its price target for the medical device company's stock to $105 from the previous $98. The upgrade is a result of extensive due diligence and recent discussions with the company's CEO.
RBC Capital Markets has expressed a renewed confidence in Medtronic's business fundamentals and management's execution capabilities. This optimism follows a period where such confidence had been absent. The firm's latest evaluations, including a non-deal roadshow (NDR) with CEO Geoff Martha on October 9, have contributed to the positive outlook.
The analyst highlighted that Medtronic is currently trading at a significant discount to the S&P 500, noting a multiple of 6 times versus a 10-year historic average of 1 times. According to RBC Capital Markets, this undervaluation is no longer warranted, and they anticipate a re-rating of Medtronic's stock.
The firm's stance is buoyed by expectations of margin expansion, earnings per share (EPS) growth, and upcoming product launches. These factors are seen as catalysts that will likely drive the company's stock performance in the near future.
Medtronic's improved rating and higher price target reflect RBC Capital Markets' outlook that the company is poised for a potential rebound. This comes at a time when the firm believes Medtronic's stock is set to align more closely with its historical market performance.
In other recent news, Medtronic has initiated a voluntary field action for its MiniMed™ 600 and 700 series insulin pumps due to potential battery issues. The FDA has categorized this as a class I recall following reports of hyperglycemia and diabetic ketoacidosis potentially related to this issue. Medtronic has been advising customers to monitor their pump's battery status and contact the company for a pump replacement if they notice a significant decrease in battery life.
In the realm of analyst notes, TD Cowen has maintained a Buy rating for Medtronic, citing the anticipated growth in the Cardiac and Spinal Technologies (CST) and Spine sectors, driven by the company's artificial intelligence-powered ecosystem, AiBLE.
Meanwhile, Piper Sandler has maintained a Neutral stance, anticipating the approval of the company's second Pulsed Field Ablation (PFA) catheter, Sphere-9, by the FDA, but advising investors to moderate their expectations due to potential manufacturing capacity challenges.
Truist Securities has raised its price target for Medtronic following the company's first-quarter earnings, which surpassed revenue expectations. The company also revised its revenue and earnings per share (EPS) guidance upwards.
However, Goldman Sachs reiterated its Sell rating on Medtronic, citing continuous growth in operating expenses and uncertainties in other operating income and expenses. Despite these recent developments, all analysts emphasize the importance of Medtronic's strategic moves in the competitive medical technology market.
InvestingPro Insights
The recent upgrade by RBC Capital Markets aligns with several key metrics and insights from InvestingPro. Medtronic's market cap stands at a robust $113.4 billion, underlining its significant presence in the Healthcare Equipment & Supplies industry. The company's P/E ratio of 29.56 suggests that investors are willing to pay a premium for its shares, possibly due to growth expectations and market position.
InvestingPro Tips highlight Medtronic's strong dividend history, having maintained dividend payments for 48 consecutive years and raised them for 10 consecutive years. This track record of consistent shareholder returns supports RBC's positive outlook on the company's fundamentals. Additionally, the stock's recent performance has been notable, with a 15.56% price total return over the past three months, indicating growing investor confidence.
The company's financial health appears solid, with InvestingPro data showing that cash flows can sufficiently cover interest payments, and liquid assets exceed short-term obligations. This financial stability could provide Medtronic with the flexibility to invest in product launches and pursue margin expansion, as anticipated by RBC Capital Markets.
For investors seeking a more comprehensive analysis, InvestingPro offers 11 additional tips for Medtronic, providing a deeper understanding of the company's potential and risks.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.